Q BioMed Inc (OTCMKTS:QBIO) announced Tuesday that its research and technology partner, Mannin Research Inc, is developing new therapeutics to treat a variety of vascular diseases, including the strain of the deadly coronavirus from Wuhan in China.
Mannin, a research-stage biotechnology company based in Toronto, has partnered with Q BioMed since 2015.
In a statement, Q BioMed said Mannin is developing a new class of drugs to treat various vascular diseases. Its lead research platform targets the activation of the Angiopoietin-Tie2 signaling pathway. In a nutshell, Angiopoietin-1 promotes sprouting and survival of endothelial cells through the activation of different signaling pathways.
The company said that while Mannin is not generating a vaccine against infectious diseases, it is developing new therapeutics that may boost survival rates by reducing endothelial dysfunction (where the inner lining of the small arteries fails to perform) by enhancing host-directed therapeutic responses.
"We are working closely with our technology research partner Mannin to develop a potential adjunct treatment for various infectious diseases like the coronavirus,” said Q BioMed CEO Denis Corin.
“These types of outbreaks are not uncommon. H1N1, SARS, Ebola, pneumonia, influenza and others all can cause vascular leakage and respiratory distress in patients, which can be fatal in the most severe cases," he added.
According to BBC, at least 427 people have died after being infected with the coronavirus and there are more than 20,000 confirmed cases around the world, most of them in China.
"Mannin's research team and collaborations in Canada, Germany, and the United States, are working to develop novel drugs to treat vascular leakage and endothelial dysfunction, which is common in severe cases of influenza, as well as in the current coronavirus outbreak,” said Mannin Research CEO George N. Nikopoulos.
Last September, Mannin received a $7.5 million grant from the German state of Saxony to fund the development of its novel therapeutics, including drugs and biologics that reduce endothelial dysfunction and loss of endothelial barrier integrity, which are central to the pathophysiology of viral and bacterial infections resulting in acute and severe lung injury.
Recently, Mannin submitted a funding application to the Small Business Technology Transfer Grant run by the US National Institutes of Health to investigate specific applications of its therapeutic platform.
Q BioMed shares added 0.90% in New York to $2.25.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive